Phase I Dose Finding Study Assessing Safety and Tolerability of SST0001 in Advanced Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2016
At a glance
- Drugs Roneparstat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Sigma-Tau Pharmaceuticals
- 01 Dec 2016 Status changed from recruiting to completed.
- 12 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Mar 2017.
- 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (n = 15).